Escher, Emanuel

Professeur associé, Faculté de médecine et des sciences de la santé
FMSS Département de pharmacologie-physiologie

Coordonnées

Courriel


819-821-8000, poste 75346


Site Web

Diplômes

(1976) Doctorat (Fellow - professionel de la santé). Swiss Federal Institute of Technology (ETH).

(1974) Doctorat (Doctorat). Swiss Federal Institute of Technology (ETH).

(1971) Diplôme (Diplôme chimie bio-organique). Swiss Federal Institute of Technology (ETH).

Présentation

Sujets de recherche

Enzymes et protéines, Maladies cardiovasculaires, Molécules bioactives, Pharmacocinétique, Signalisation cellulaire.

Disciplines de recherche

Biochimie, Pharmacologie.

Mots-clés

Bio-capteurs, Chimie organique sur phas, Marquage photoaffinité, Modelage moléculaire, Modification chimique de, Mutagénèse dirigée, Pharmacocinétique pré-clinique, Récepteur couplé Gprot.

Intérêts de recherche

Développement et utilisation d'outils moléculaires pour l'étude des récepteurs peptidergiques. Biosenseurs, chimie de surfaces, nanotechnologies Pharmacocinétique pré-clinique

Centre de recherche

Centre de recherche du CHUS

Langues parlées et écrites

Allemand, Anglais, Français, Italien

Prix et distinctions

  • Prix Étienne Lebel. (Distinction).

Publications

Articles de revue

  • Domazet I , Holleran BJ , Richard A , Vandenberghe C , Lavigne P , Escher E , Leduc R , Guillemette G. (2015). Characterization of Angiotensin II Molecular Determinants Involved in AT1 Receptor Functional Selectivity. Molecular pharmacology, 87(6), 982-95. (Article publié).
  • Cabana J , Holleran B , Leduc R , Escher E , Guillemette G , Lavigne P. (2015). Identification of distinct conformations of the angiotensin-II type 1 receptor associated with the Gq/11 pathway and the beta-arrestin pathway using molecular dynamics simulations. The Journal of biological chemistry, (Article publié).
  • Boulais PE , Escher E , Leduc R. (2013). Analysis by substituted cysteine scanning mutagenesis of the fourth transmembrane domain of the CXCR4 receptor in its inactive and active state. Biochemical pharmacology, 85(4),
  • Cabana J , Holleran B , Beaulieu MÈ , Leduc R , Escher E , Guillemette G , Lavigne P. (2013). Critical hydrogen bond formation for activation of the angiotensin II type 1 receptor. The Journal of biological chemistry, 288(4),
  • Sainsily X , Cabana J , Boulais PE , Holleran BJ , Escher E , Lavigne P , Leduc R. (2013). Identification of transmembrane domain 3, 4 & 5 residues that contribute to the formation of the ligand-binding pocket of the urotensin-II receptor. Biochemical pharmacology, 86(11), 1584-93. (Article publié).
  • Sainsily X , Cabana J , Boulais PE , Holleran BJ , Escher E , Lavigne P , Leduc R. (2013). Identification of transmembrane domain 3, 4 & 5 residues that contribute to the formation of the ligand-binding pocket of the urotensin-II receptor. Biochemical pharmacology, 86(11),
  • Fillion D , Cabana J , Guillemette G , Leduc R , Lavigne P , Escher E. (2013). Structure of the human angiotensin II type 1 (AT1) receptor bound to angiotensin II from multiple chemoselective photoprobe contacts reveals a unique peptide binding mode. The Journal of biological chemistry, 288(12),
  • Lefrançois ML, Lefebvre M-R, Boulais P, Cabana J, Mona C, St-Louis E, Lavigne P, Lesic R, Heveker N, Escher E. (2012). Binding, signaling and in vivo efficacity of novel peptidic CXCR4 agonists. 32 EPS Peptides 2012. September 2 – 7, 2012., 32 EPS Peptides 2012(32), (Article publié).
  • Zimmerman B , Beautrait A , Aguila B , Charles R , Escher E , Claing A , Bouvier M , Laporte SA. (2012). Differential β-arrestin-dependent conformational signaling and cellular responses revealed by angiotensin analogs. Science signaling, 5(221),
  • Wangler NJ , Santos KL , Schadock I , Hagen FK , Escher E , Bader M , Speth RC , Karamyan VT. (2012). Identification of membrane-bound variant of metalloendopeptidase neurolysin (EC 3.4.24.16) as the non-angiotensin type 1 (non-AT1), non-AT2 angiotensin binding site. The Journal of biological chemistry, 287(1),
  • Marilou Lefrancois, Christine Mona, Marie-Reine Lefebvre, Richard Leduc, Pierre Lavigne, Nikolaus Heveker, and Emanuel Escher. (2012). Structural Determinants of Gi Activation by Peptidic CXCR4 Agonists. Proceedings of the 23rd American Peptide Symposium, (Article sous presse).
  • Jérome Cabana, Dany Fillion, Gaétan Guillemette, Richard Leduc, Pierre Lavigne, and Emanuel Escher. (2012). Structure of the Human AT1 Receptor Bound to Angiotensin II: Structural Basis of Previous SAR Findings. Proceedings of the 23rd American Peptide Symposium, (Article sous presse).
  • (2012). Synthesis of CXCR4 specific agonists: SAR studies on the agonist-antagonist transition. 32 EPS Peptides 2012, 32, (Article publié).
  • Christine Mona, Marilou Lefrançois, Philip E. Boulais, Élie Besserer-Offroy, Richard Leduc, Nikolaus Heveker, Éric Marsault, and Emanuel Escher. (2012). Synthetic Agonists for the CXCR4 Receptor: SAR, Signaling Pathways and Peptidomimetic Transition. Proceedings of the 23rd American Peptide Symposium, (Article sous presse).
  • Lefrançois M , Lefebvre MR , Saint-Onge G , Boulais PE , Lamothe S , Leduc R , Lavigne P , Heveker N , Escher E. (2011). Agonists for the Chemokine Receptor CXCR4. ACS medicinal chemistry letters, 2(8),
  • Yan L , Holleran BJ , Lavigne P , Escher E , Guillemette G , Leduc R. (2010). Analysis of transmembrane domains 1 and 4 of the human angiotensin II AT1 receptor by cysteine-scanning mutagenesis. The Journal of biological chemistry, 285(4),
  • Arsenault J , Lehoux J , Lanthier L , Cabana J , Guillemette G , Lavigne P , Leduc R , Escher E. (2010). A single-nucleotide polymorphism of alanine to threonine at position 163 of the human angiotensin II type 1 receptor impairs Losartan affinity. Pharmacogenetics and genomics, 20(6),
  • Karamyan VT , Arsenault J , Escher E , Speth RC. (2010). Preliminary biochemical characterization of the novel, non-AT1, non-AT2 angiotensin binding site from the rat brain. Endocrine, 37(3),
  • Fillion D , Lemieux G , Basambombo LL , Lavigne P , Guillemette G , Leduc R , Escher E. (2010). The amino-terminus of angiotensin II contacts several ectodomains of the angiotensin II receptor AT1. Journal of medicinal chemistry, 53(5),
  • Clément M , Cabana J , Holleran BJ , Leduc R , Guillemette G , Lavigne P , Escher E. (2009). Activation induces structural changes in the liganded angiotensin II type 1 receptor. The Journal of biological chemistry, 284(39),
  • Chabot V , Cuerrier CM , Escher E , Aimez V , Grandbois M , Charette PG. (2009). Biosensing based on surface plasmon resonance and living cells. Biosensors & bioelectronics, 24(6),
  • Holleran BJ , Domazet I , Beaulieu ME , Yan LP , Guillemette G , Lavigne P , Escher E , Leduc R. (2009). Identification of transmembrane domain 6 & 7 residues that contribute to the binding pocket of the urotensin II receptor. Biochemical pharmacology, 77(8),
  • Jastrzebska B , Lebel R , McIntyre OJ , Paquette B , Neugebauer W , Escher E , Lepage M. (2009). Monitoring of MMPs activity in vivo, non-invasively, using solubility switchable MRI contrast agent. Advances in experimental medicine and biology, 611,
  • Wieczerzak E , Hame R , Chabot V , Aimez V , Charette PG , Grandbois M , Escher E. (2009). Monitoring of native chemical ligation by surface plasmon resonance. Advances in experimental medicine and biology, 611,
  • Jastrzebska B , Lebel R , Therriault H , McIntyre JO , Escher E , Guérin B , Paquette B , Neugebauer WA , Lepage M. (2009). New enzyme-activated solubility-switchable contrast agent for magnetic resonance imaging: from synthesis to in vivo imaging. Journal of medicinal chemistry, 52(6),
  • Boulais PE , Dulude D , Cabana J , Heveker N , Escher E , Lavigne P , Leduc R. (2009). Photolabeling identifies transmembrane domain 4 of CXCR4 as a T140 binding site. Biochemical pharmacology, 78(11),
  • Domazet I , Martin SS , Holleran BJ , Morin ME , Lacasse P , Lavigne P , Escher E , Leduc R , Guillemette G. (2009). The fifth transmembrane domain of angiotensin II Type 1 receptor participates in the formation of the ligand-binding pocket and undergoes a counterclockwise rotation upon receptor activation. The Journal of biological chemistry, 284(46),
  • Domazet I , Holleran BJ , Martin SS , Lavigne P , Leduc R , Escher E , Guillemette G. (2009). The second transmembrane domain of the human type 1 angiotensin II receptor participates in the formation of the ligand binding pocket and undergoes integral pivoting movement during the process of receptor activation. The Journal of biological chemistry, 284(18),
  • Proulx CD , Holleran BJ , Lavigne P , Escher E , Guillemette G , Leduc R. (2008). Biological properties and functional determinants of the urotensin II receptor. Peptides, 29(5),
  • Proulx CD , Holleran BJ , Boucard AA , Escher E , Guillemette G , Leduc R. (2008). Mutational analysis of the conserved Asp2.50 and ERY motif reveals signaling bias of the urotensin II receptor. Molecular pharmacology, 74(3),
  • Lebel R , Jastrzebska B , Therriault H , Cournoyer MM , McIntyre JO , Escher E , Neugebauer W , Paquette B , Lepage M. (2008). Novel solubility-switchable MRI agent allows the noninvasive detection of matrix metalloproteinase-2 activity in vivo in a mouse model. Magnetic resonance in medicine : official journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine, 60(5),
  • Cuerrier CM , Chabot V , Vigneux S , Aimez V , Escher E , Gobeil F , Charette PG , Grandbois M. (2008). Surface Plasmon Resonance Monitoring of Cell Monolayer Integrity: Implication of Signaling Pathways Involved in Actin-Driven Morphological Remodeling. Cellular and molecular bioengineering, 1(4),

Articles de journaux

  • Sainsily X , Cabana J , Holleran BJ , Escher E , Lavigne P , Leduc R. (2014). Identification of transmembrane domain 1 & 2 residues that contribute to the formation of the ligand-binding pocket of the urotensin-II receptor. Biochemical pharmacology.